SCHEMBL3465056

SCHEMBL3465056

O=C(NCC(O)CO)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.64
RAB9A P51151 3/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
BACE1 P56817 1/20 0.58
KDM4E B2RXH2 1/20 0.57
ALDH1A1 P00352 1/20 0.57
HPGD P15428 1/20 0.57
GAA P10253 2/20 0.57
PRMT5 O14744 3/20 0.52
WDR77 Q9BQA1 1/20 0.52
EPHX2 P34913 1/20 0.50
CNR2 P34972 1/20 0.49
EGFR P00533 1/20 0.48
SRC P12931 1/20 0.48
KMT2A Q03164 1/20 0.47
HSD17B10 Q99714 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
PRSS1 P07477 1/20 0.46
CTSG P08311 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6154030 1.00 NPC1 (0.64) NPC1RAB9ASMN1; SMN2BACE1KDM4E
Hydrochloric Acid SCHEMBL27854881 0.98 NPC1 (0.62) NPC1RAB9ASMN1; SMN2BACE1KDM4E
SCHEMBL21211563 0.87 GAA (0.64) NPC1RAB9ASMN1; SMN2BACE1KDM4E
SCHEMBL9844761 0.86 TP53 (0.57) NPC1RAB9ASMN1; SMN2BACE1KDM4E
SCHEMBL29280658 0.84 NPC1 (0.62) NPC1RAB9ASMN1; SMN2BACE1GAA
SCHEMBL9830287 0.84 NPC1 (0.62) NPC1RAB9ASMN1; SMN2BACE1ALDH1A1
SCHEMBL28341767 0.84 NPC1 (0.62) NPC1RAB9ASMN1; SMN2BACE1ALDH1A1
SCHEMBL6153995 0.84 NPC1 (0.62) NPC1RAB9ASMN1; SMN2BACE1GAA
SCHEMBL6153998 0.84 NPC1 (0.62) NPC1RAB9ASMN1; SMN2BACE1GAA
SCHEMBL14790184 0.83 GAA (0.58) NPC1RAB9ASMN1; SMN2BACE1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104017153-B Polylactic acid resin composition 三井化学株式会社 2017-01-11 CN disclosed
CN-104736759-B Carbon fiber-reinforced resin composition, the manufacture method of carbon fiber-reinforced resin composition, moulding material, the manufacture method of moulding material and carbon fiber-reinforced resin products formed 东丽株式会社 2016-12-07 CN disclosed
CN-104684975-B Prepreg and carbon fibre reinforced composite 东丽株式会社 2016-11-23 CN disclosed
CN-106012108-A Sizing-agent-coated carbon fibre bundle and prepreg 东丽株式会社 2016-10-12 CN disclosed
CN-104487495-B Prepreg and carbon fibre reinforced composite 东丽株式会社 2016-09-07 CN disclosed
EP-2248820-B1 Universal supports for oligonucleotide synthesis GLEN RES CORP (US) 2014-01-08 EP disclosed
EP-1404695-B1 UNIVERSAL SUPPORTS FOR OLIGONUCLEOTIDE SYNTHESIS GLEN RES CORP (US) 2013-04-10 EP disclosed
EP-2248820-A1 Universal supports for oligonucleotide synthesis Glen Research Corporation (US) 2010-11-10 EP disclosed
US-7491817-B2 Universal supports for oligonucleotide synthesis GLEN RESEARCH CORPORATION (US) 2009-02-17 US disclosed
US-20050250116-A1 Universal supports for oligonucleotide synthesis GLEN RESEARCH CORPORATION (US) 2005-11-10 US disclosed
US-20020137855-A1 Universal supports for oligonucleotide synthesis GLEN RESEARCH CORPORATION (US) 2002-09-26 US disclosed
US-6448373-B1 INHIBITORS OF ENZYMES SUCH AS PHOSPHOLIPASE A2; TREATMENT OF INFLAMMATORY DISEASES INCLUDING ATOPIC DERMATITIS AND INFLAMMATORY BOWEL DISEASE ISIS PHARMACEUTICALS, INC. 2002-09-10 US disclosed
WO-2002044398-A2 UNIVERSAL SUPPORTS FOR OLIGONUCLEOTIDE SYNTHESIS GLEN RESEARCH CORPORATION (US) 2002-06-06 WO disclosed
EP-0739351-B1 MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM ISIS PHARMACEUTICALS INC (US) 2002-04-10 EP disclosed
WO-1999026932-A1 BY AMIDINO GROUP SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTICOAGULANTS AXYS PHARMACEUTICALS, INC. (US) 1999-06-03 WO disclosed
US-5886177-A ETHYLENE GLYCOL MONOMERS JOINED VIA STANDARD PHOSPHATE LINKAGES INCLUDING PHOSPHOROTHIOATE, PHOSPHODIESTER, AND PHOSPHORAMIDATE LINKAGES; USEFUL FUNCTIONAL GROUPS INCLUDE NUCLEOBASES AS WELL AS POLAR GROUPS, HYDROPHOBIC GROUPS ISIS PHARMACEUTICALS, INC. (US) 1999-03-23 US disclosed
EP-0739351-A4 MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM ISIS PHARMACEUTICALS INC (US) 1998-10-21 EP disclosed
CN-1164225-A Iodinated X-ray-contrast media NYCOMED IMAGING AS (NO) 1997-11-05 CN disclosed
EP-0739351-A1 MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM ISIS PHARMACEUTICALS, INC. (US) 1996-10-30 EP disclosed
WO-1995018820-A1 MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM ISIS PHARMACEUTICALS, INC. (US) 1995-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250116-A1 Universal supports for oligonucleotide synthesis FBL, NSUN2, NOP2 NPC1 4331/4885RAB9A 4056/4885SMN1; SMN2 1284/4885
US-20020137855-A1 Universal supports for oligonucleotide synthesis FBL, NSUN2, NOP2 NPC1 4409/4885RAB9A 3970/4885SMN1; SMN2 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.